Q32 Bio presents additional Bempikibart efficacy and durability data
Q32 Bio released late-breaking efficacy and off-drug durability data for bempikibart. The results support a potential registration-directed program and advances the company in the competitive alopecia areata market.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed